September 4th 2025
Dr Ramtohul's research uses electrophysiologic testing to study the retinal ganglion cells
September 3rd 2025
The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).
September 1st 2025
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
August 28th 2025
Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings
August 27th 2025
An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration
Industry preview: Ophthalmic companies bring updates, new research findings to EURETINA
Businesses in the retina care space tease new technologies and cutting-edge therapeutics
Celebrate World Retina Day at the 2024 EURETINA Congress
As part of the Barcelona meeting, retina specialists can recognise the awareness day early
24th EURETINA Congress: The art of retina on stage in Barcelona
Focus on collaboration, career development and innovation
Remembering a legend: EURETINA members speak about the Ramin Tadayoni Award
The Ramin Tadayoni Award supports the next generation of retina researchers while paying tribute to a leader in the field
The digital OR: Retina care of tomorrow
The future of the tech-forward surgical suite
Research findings illustrate role of vitamin D in preventing retinal vein occlusion
A meta-analysis indicates a "significant association" between vitamin D deficiency and increased risk of RVO
A field guide to optic disc drusen
Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilloedema
Ranibizumab biosimilar LUBT010 (Lupin) reaches primary endpoint in global Phase 3 study
Lupin has successfully completed a clinical study of LUBT010, a ranibizumab biosimilar to Lucentis
ASRS abroad: Retina specialists converge in Sweden
A postcard from the American Society of Retina Specialists meeting in Stockholm
European Commission issues approval for faricimab (Vabysmo) for treatment of retinal vein occlusion
In a press release, Roche noted that up to 60% of patients were able to extend treatment intervals to 3 or 4 months
Kiora Pharmaceuticals receives Orphan Medicinal Product Designation for KIO-301
The EMA issued a designation for the small molecule photoswitch, which targets inherited retinal diseases including retinitis pigmentosa
ASRS 2024: Real-world treatment outcomes from a study of patients with retinal vein occlusion
Consultant ophthalmologist Christiana Dinah, BSc, MB BS, MRes, presented research findings on retinal vein occlusion in the United Kingdom
ASRS 2024: Real-world impact of vitrectomy surgery on age-related macular degeneration
Chase Ludwig, MD, speaks about the effect of vitrectomy on the progression of age-related macular degeneration
ASRS 2024: Clinical characterisation of HK1 associated with retinitis pigmentosa
At this year's ASRS meeting, Patrick C. Staropoli, MD, discussed his presentation about autosomal dominant pericentral retinitis pigmentosa
ASRS 2024: Sickle cell retinopathy and measurements with dynamic OCT angiography
Richard B. Rosen, MD, recipient of the ASRS Founders Award for 2024, discusses his presentation at the meeting
ASRS 2024: Social determinants of vision health in patients with rhegmatogenous retinal detachments
At this year's ASRS meeting, Sally S. Ong, MD, shared results from a 10-year study on socioeconomic barriers and visual outcomes
ASRS 2024: Examining 36-month outcomes of fluocinolone acetonide 0.18 with the CALM registry study
Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg
ASRS 2024: A novel approach to myopic traction maculopathy
Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024
ASRS 2024: Aflibercept 8 mg and 2 mg, DME, and IOP outcomes in the phase 2/3 PHOTON trial
Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial
ASRS 2024: Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
Eleonora Lad, MD, PhD, discusses multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
ASRS 2024: Intraoperative fluorescein angiography reduces the rate of postoperative vitreous hemorrhage
Alan Franklin, MD, PhD, FASRS, a retina specialist in Mobile, Alabama spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage."
ASRS 2024: Long-term results of macular hole surgery with long-acting gas tamponade
John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes
ASRS 2024: 100-week results from the RESTORE trial showcase retinitis pigmentosa outcomes
Michael Singer, MD, speaks at the American Society of Retina Specialists meeting
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time
Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide use in non-infectious uveitis
Ahead of the ASRS meeting in Stockholm, Sweden, Danny Mammo, MD, discusses use of suprachoroidal triamcinolone acetonide in non-infectious uveitis
ASRS 2024: First-time results from a phase 1b study of FAS inhibition with ONL-1204
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204 for the treatment of geographic atrophy
ASRS 2024: Examining real-world use of faricimab through the FARETINA-DME Study
Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study
ASRS 2024: Geographic atrophy findings from part 1 of the Phase 2/3 SIGLEC trial
Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy
ASRS 2024: Continuous treatment of DME with a port delivery system for ranibizumab
Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results
ASRS 2024: 72-Week results from the Phase 3 BALATON and COMINO trials
Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion